Anti-Müllerian hormone and risk of ovarian cancer in nine cohorts
Animal and experimental data suggest that anti-Müllerian hormone (AMH) serves as a marker of ovarian reserve and inhibits the growth of ovarian tumors. However, few epidemiologic studies have examined the association between AMH and ovarian cancer risk. We conducted a nested case-control study of 30...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Wiley
2017
|
| _version_ | 1797105161885188096 |
|---|---|
| author | Jung, S Allen, N Arslan, AA Baglietto, L Barricarte, A Brinton, LA Egleston, BL Falk, RT Fortner, RT Helzlsouer, KJ Gao, Y Idahl, A Kaaks, R Krogh, V Merritt, MA Lundin, E Onland-Moret, NC Rinaldi, S Schock, H Shu, X-O Sluss, PM Staats, PN Sacerdote, C Travis, RC Tjønneland, A Trichopoulou, A Tworoger, SS Visvanathan, K Weiderpass, E Zeleniuch-Jacquotte, A Dorgan, JF |
| author_facet | Jung, S Allen, N Arslan, AA Baglietto, L Barricarte, A Brinton, LA Egleston, BL Falk, RT Fortner, RT Helzlsouer, KJ Gao, Y Idahl, A Kaaks, R Krogh, V Merritt, MA Lundin, E Onland-Moret, NC Rinaldi, S Schock, H Shu, X-O Sluss, PM Staats, PN Sacerdote, C Travis, RC Tjønneland, A Trichopoulou, A Tworoger, SS Visvanathan, K Weiderpass, E Zeleniuch-Jacquotte, A Dorgan, JF |
| author_sort | Jung, S |
| collection | OXFORD |
| description | Animal and experimental data suggest that anti-Müllerian hormone (AMH) serves as a marker of ovarian reserve and inhibits the growth of ovarian tumors. However, few epidemiologic studies have examined the association between AMH and ovarian cancer risk. We conducted a nested case-control study of 302 ovarian cancer cases and 336 matched controls from nine cohorts. Prediagnostic blood samples of premenopausal women were assayed for AMH using a picoAMH enzyme-linked immunosorbent assay. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using multivariable-adjusted conditional logistic regression. AMH concentration was not associated with overall ovarian cancer risk. The multivariable-adjusted OR (95% CI), comparing the highest to the lowest quartile of AMH, was 0.99 (0.59-1.67) (Ptrend : 0.91). The association did not differ by age at blood draw or oral contraceptive use (all Pheterogeneity : ≥0.26). There also was no evidence for heterogeneity of risk for tumors defined by histologic developmental pathway, stage, and grade, and by age at diagnosis and time between blood draw and diagnosis (all Pheterogeneity : ≥0.39). In conclusion, this analysis of mostly late premenopausal women from nine cohorts does not support the hypothesized inverse association between prediagnostic circulating levels of AMH and risk of ovarian cancer. |
| first_indexed | 2024-03-07T06:43:30Z |
| format | Journal article |
| id | oxford-uuid:fa18e1c9-8048-4c15-8f04-474fbd87196f |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T06:43:30Z |
| publishDate | 2017 |
| publisher | Wiley |
| record_format | dspace |
| spelling | oxford-uuid:fa18e1c9-8048-4c15-8f04-474fbd87196f2022-03-27T13:03:07ZAnti-Müllerian hormone and risk of ovarian cancer in nine cohortsJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:fa18e1c9-8048-4c15-8f04-474fbd87196fEnglishSymplectic Elements at OxfordWiley2017Jung, SAllen, NArslan, AABaglietto, LBarricarte, ABrinton, LAEgleston, BLFalk, RTFortner, RTHelzlsouer, KJGao, YIdahl, AKaaks, RKrogh, VMerritt, MALundin, EOnland-Moret, NCRinaldi, SSchock, HShu, X-OSluss, PMStaats, PNSacerdote, CTravis, RCTjønneland, ATrichopoulou, ATworoger, SSVisvanathan, KWeiderpass, EZeleniuch-Jacquotte, ADorgan, JFAnimal and experimental data suggest that anti-Müllerian hormone (AMH) serves as a marker of ovarian reserve and inhibits the growth of ovarian tumors. However, few epidemiologic studies have examined the association between AMH and ovarian cancer risk. We conducted a nested case-control study of 302 ovarian cancer cases and 336 matched controls from nine cohorts. Prediagnostic blood samples of premenopausal women were assayed for AMH using a picoAMH enzyme-linked immunosorbent assay. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using multivariable-adjusted conditional logistic regression. AMH concentration was not associated with overall ovarian cancer risk. The multivariable-adjusted OR (95% CI), comparing the highest to the lowest quartile of AMH, was 0.99 (0.59-1.67) (Ptrend : 0.91). The association did not differ by age at blood draw or oral contraceptive use (all Pheterogeneity : ≥0.26). There also was no evidence for heterogeneity of risk for tumors defined by histologic developmental pathway, stage, and grade, and by age at diagnosis and time between blood draw and diagnosis (all Pheterogeneity : ≥0.39). In conclusion, this analysis of mostly late premenopausal women from nine cohorts does not support the hypothesized inverse association between prediagnostic circulating levels of AMH and risk of ovarian cancer. |
| spellingShingle | Jung, S Allen, N Arslan, AA Baglietto, L Barricarte, A Brinton, LA Egleston, BL Falk, RT Fortner, RT Helzlsouer, KJ Gao, Y Idahl, A Kaaks, R Krogh, V Merritt, MA Lundin, E Onland-Moret, NC Rinaldi, S Schock, H Shu, X-O Sluss, PM Staats, PN Sacerdote, C Travis, RC Tjønneland, A Trichopoulou, A Tworoger, SS Visvanathan, K Weiderpass, E Zeleniuch-Jacquotte, A Dorgan, JF Anti-Müllerian hormone and risk of ovarian cancer in nine cohorts |
| title | Anti-Müllerian hormone and risk of ovarian cancer in nine cohorts |
| title_full | Anti-Müllerian hormone and risk of ovarian cancer in nine cohorts |
| title_fullStr | Anti-Müllerian hormone and risk of ovarian cancer in nine cohorts |
| title_full_unstemmed | Anti-Müllerian hormone and risk of ovarian cancer in nine cohorts |
| title_short | Anti-Müllerian hormone and risk of ovarian cancer in nine cohorts |
| title_sort | anti mullerian hormone and risk of ovarian cancer in nine cohorts |
| work_keys_str_mv | AT jungs antimullerianhormoneandriskofovariancancerinninecohorts AT allenn antimullerianhormoneandriskofovariancancerinninecohorts AT arslanaa antimullerianhormoneandriskofovariancancerinninecohorts AT bagliettol antimullerianhormoneandriskofovariancancerinninecohorts AT barricartea antimullerianhormoneandriskofovariancancerinninecohorts AT brintonla antimullerianhormoneandriskofovariancancerinninecohorts AT eglestonbl antimullerianhormoneandriskofovariancancerinninecohorts AT falkrt antimullerianhormoneandriskofovariancancerinninecohorts AT fortnerrt antimullerianhormoneandriskofovariancancerinninecohorts AT helzlsouerkj antimullerianhormoneandriskofovariancancerinninecohorts AT gaoy antimullerianhormoneandriskofovariancancerinninecohorts AT idahla antimullerianhormoneandriskofovariancancerinninecohorts AT kaaksr antimullerianhormoneandriskofovariancancerinninecohorts AT kroghv antimullerianhormoneandriskofovariancancerinninecohorts AT merrittma antimullerianhormoneandriskofovariancancerinninecohorts AT lundine antimullerianhormoneandriskofovariancancerinninecohorts AT onlandmoretnc antimullerianhormoneandriskofovariancancerinninecohorts AT rinaldis antimullerianhormoneandriskofovariancancerinninecohorts AT schockh antimullerianhormoneandriskofovariancancerinninecohorts AT shuxo antimullerianhormoneandriskofovariancancerinninecohorts AT slusspm antimullerianhormoneandriskofovariancancerinninecohorts AT staatspn antimullerianhormoneandriskofovariancancerinninecohorts AT sacerdotec antimullerianhormoneandriskofovariancancerinninecohorts AT travisrc antimullerianhormoneandriskofovariancancerinninecohorts AT tjønnelanda antimullerianhormoneandriskofovariancancerinninecohorts AT trichopouloua antimullerianhormoneandriskofovariancancerinninecohorts AT tworogerss antimullerianhormoneandriskofovariancancerinninecohorts AT visvanathank antimullerianhormoneandriskofovariancancerinninecohorts AT weiderpasse antimullerianhormoneandriskofovariancancerinninecohorts AT zeleniuchjacquottea antimullerianhormoneandriskofovariancancerinninecohorts AT dorganjf antimullerianhormoneandriskofovariancancerinninecohorts |